Skip to main content

Renal Transplant Rejection

Nephrology
9
Pipeline Programs
9
Companies
10
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
1
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 13 programs with unclassified modality

Nephrology is a $36.6B mature market dominated by cardiometabolic crossover drugs with limited pure renal innovation.

$36.6B marketMature→ Stable30 products15 companies

Key Trends

  • GLP-1 agonists and SGLT2 inhibitors dominate (69% of spending) due to dual cardio-renal benefits
  • Patent cliffs approaching 2026-2030 create generic conversion risk for blockbuster franchises
  • Pipeline activity remains robust (2,785 trials) but concentrated in early-phase basic research

Career Verdict

Nephrology offers stable employment in commercial and medical affairs roles, but limited growth upside due to mature blockbuster dependency and declining pure renal research focus.

AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data

Market Leaders

#1OZEMPICStable
$9.2B
Novo Nordisk·Peak12.4yr
#2JARDIANCEStable
$8.8B
#4FARXIGAStable
$4.3B
AstraZeneca·Peak15.4yr

Drug Class Breakdown

Glucagon-like Peptide-1 (GLP-1) Agonists
$16.6B(45%)

cardiometabolic dominance

Sodium-Glucose Transporter 2 Inhibitors
$8.8B(24%)

cardioprotective expansion

SGLT2 Inhibitors (dapagliflozin class)
$4.3B(12%)

heart failure crossover

Adrenergic Beta3-Agonists
$3.0B(8%)

overactive bladder niche

Dipeptidyl Peptidase 4 Inhibitors
$1.3B(4%)

declining relevance

Career Outlook

Stable

Nephrology careers are stable but not expanding; the field is supported by blockbuster drugs (GLP-1s, SGLT2i) that face patent cliffs between 2026–2041, creating near-term employment security but long-term uncertainty. Commercial and medical affairs roles dominate hiring, while R&D investment is limited to niche mechanisms (complement inhibition, gene therapy). Career progression depends on specialization in medtech, diagnostics, or orphan nephrology rather than traditional pharma blockbuster development.

Breaking In

Target medtech platforms (Outset, Fresenius) or biotech innovators (Vertex, Calyxo) over traditional pharma; nephrology offers job stability and clinical depth but limited growth trajectory in pure pharmaceutical roles.

For Experienced Professionals

Leverage cardiometabolic expertise to span diabetes, CKD, and HF franchises; position for transition to orphan nephrology (ADPKD, FSGS, IgA) where innovation and valuation multiples are highest.

In-Demand Skills

Renal endpoints and biomarkers (eGFR, albuminuria)Cardio-renal crossover knowledge (diabetes + CKD + HF)Medtech systems expertise (dialysis, transplantation platforms)Medical affairs and key opinion leader management

Best For

Medical Science Liaison (renal specialists)Commercial Manager (established nephro franchise)Clinical Development Manager (rare kidney disease)Real-world evidence analyst (CKD outcomes)

Hiring Landscape

$108K–$330K

Nephrology hiring is concentrated in commercial roles (58 positions, $108K avg) and medical affairs (12 positions, $330K avg), reflecting mature market dynamics. Top hiring companies are innovative platforms (Vertex: 41 jobs) and medtech (Outset: 21 jobs), not traditional pharma. Salary compression in commercial roles suggests commoditization.

124
Open Roles
5
Companies Hiring
4
Departments

Top Hiring Companies

20Growing
8Stable

By Department

Commercial(47%)
$108K
Medical Affairs(10%)
$330K
Clinical Excellence(6%)
$140K
Quality Assurance(4%)
$201K

Hiring favors medtech and biotech platforms over traditional pharma; medical affairs offers premium compensation but limited volume; commercial roles are abundant but underpaid relative to other therapeutic areas.

On Market (1)

Approved therapies currently available

Bristol Myers Squibb
NULOJIXApproved
belatacept
Bristol Myers Squibb
Selective T Cell Costimulation Blocker [EPC]injection2011
5M Part D

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
3 programs
2
EverolimusPhase 41 trial
SimulectPhase 41 trial
Micro samplingN/A1 trial
Active Trials
NCT03512431Completed27Est. Nov 2018
NCT01239472Completed30Est. Jun 2015
NCT02377193Completed60Est. Jan 2017
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
3 programs
1
2
BelataceptPhase 41 trial
PrografPhase 41 trial
Donor CD34+ and CD3+ cellsPhase 1/21 trial
Active Trials
NCT03707262Recruiting15Est. Feb 2026
NCT01953120Completed20Est. Apr 2021
NCT02866682Completed176Est. Jun 2021
Neovii Biotech
Neovii BiotechGermany - Grafelfing
2 programs
1
1
SimulectPhase 4
ATG-Fresenius SPhase 31 trial
Active Trials
NCT01324934Terminated40Est. Jan 2011
Bristol Myers Squibb
1 program
1
BelataceptPHASE_4
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
belimumabPhase 1/2Monoclonal Antibody
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
VIRTUUS Children's StudyN/A1 trial
Active Trials
NCT03719339Active Not Recruiting445Est. Mar 2026
GE HealthCare
1 program
SonazoidPHASE_21 trial
Active Trials
NCT02733029Completed8Est. Feb 2023
Novartis
NovartisBASEL, Switzerland
1 program
SimulectPHASE_4
Veloxis Pharmaceuticals
1 program
Tacrolimus Extended Release Oral TabletPHASE_41 trial
Active Trials
NCT03511560Completed50Est. Jul 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Veloxis PharmaceuticalsTacrolimus Extended Release Oral Tablet
Angeles TherapeuticsPrograf
Angeles TherapeuticsBelatacept
SandozSimulect
SandozEverolimus
Neovii BiotechATG-Fresenius S
GE HealthCareSonazoid
Angeles TherapeuticsDonor CD34+ and CD3+ cells
SandozMicro sampling
Human BioSciencesVIRTUUS Children's Study

Clinical Trials (10)

Total enrollment: 871 patients across 10 trials

NCT03511560Veloxis PharmaceuticalsTacrolimus Extended Release Oral Tablet

Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation

Start: Jul 2018Est. completion: Jul 202150 patients
Phase 4Completed

Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients

Start: Mar 2018Est. completion: Jun 2021176 patients
Phase 4Completed

Mechanisms of Belatacept Effect on Alloimmunity and Antiviral Response After Kidney Transplantation (BMS IM 103-309)

Start: Oct 2013Est. completion: Apr 202120 patients
Phase 4Completed

Simulect Versus ATG in Sensitized Renal Transplant Patient

Start: Sep 2013Est. completion: Jan 201760 patients
Phase 4Completed

Cytokines Evaluation in Early Calcineurin Inhibitors Withdrawn on Renal Transplant

Start: Jan 2011Est. completion: Jun 201530 patients
Phase 4Completed

Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids

Start: Oct 2006Est. completion: Jan 201140 patients
Phase 3Terminated

Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection

Start: May 2018Est. completion: Feb 20238 patients
Phase 2Completed
NCT03707262Angeles TherapeuticsDonor CD34+ and CD3+ cells

Study of Combined Kidney and Blood Stem Cell Transplant From a Brother or Sister Donor

Start: Nov 2019Est. completion: Feb 202615 patients
Phase 1/2Recruiting
NCT03512431SandozMicro sampling

Dose Adjustment of Tacrolimus Based on Home Sampling in Renal Transplant Recipients

Start: Apr 2018Est. completion: Nov 201827 patients
N/ACompleted
NCT03719339Human BioSciencesVIRTUUS Children's Study

VIRTUUS Children's Study

Start: Aug 2017Est. completion: Mar 2026445 patients
N/AActive Not Recruiting

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 871 patients
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.